← Dashboard
Oct 26, 2026 01:04 AM ET
Signal
FDA/Bio
Roche lung cancer drug extends survival by nearly six months in late-stage trial
Late-stage trial shows Roche lung cancer drug extends survival by nearly six months.
What changed
Late-stage trial shows Roche lung cancer drug extends survival by nearly six months.
Why it matters
Late-stage trial shows Roche lung cancer drug extends survival by nearly six months. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
In reversal, American Cancer Society urges routine prostate cancer screening →
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →
PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →